

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael David Lynch-Bell
Date of last notice	4 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	3 April 2024
No. of securities held prior to change	1,688,450 Ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 280,000 Retention share rights
Class	(a) Ordinary shares (b) Retention share rights
Number acquired	(a) 70,000
Number disposed	(b) 70,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil - shares issued on exercise of vested retention share rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	1,758,450 Ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 210,000 Retention Share Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of retention share rights issued in September 2021 which vested in February 2024 after continuous service to the Company

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neale William Fong
Date of last notice	4 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director and beneficiary of the trust Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee and beneficiary of the trust
Date of change	3 April 2024
No. of securities held prior to change	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares Dr Neale Fong <Damblock Trust> 1,219,575 Ordinary shares 140,000 Retention Share Rights 125,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
Class	(a) Ordinary shares (b) Retention share rights
Number acquired	(a) 35,000
Number disposed	(b) 35,000

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil - shares issued on exercise of vested retention share rights
No. of securities held after change	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares Dr Neale Fong <Damblock Trust> 1,254,575 Ordinary shares 105,000 Retention Share Rights 125,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of retention share rights issued in September 2021 which vested in February 2024 after continuous service to the Company

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.